TIME100 Health: Laura Esserman

The UCSF-led WISDOM randomized trial (launched 2016) found that personalized, risk-based breast cancer screening yielded similar overall cancer diagnosis rates to standard annual mammography while reducing diagnoses of stage 2B cancers, a stage associated with sharply higher mortality. The findings imply current one-size-fits-all screening may overdiagnose low-risk women and miss higher-risk cases, strengthening the case for policy shifts toward comprehensive risk-stratified screening; disclosure notes UCSF donors include Marc and Lynne Benioff.

Analysis

Market structure: Risk-stratified breast screening disproportionately favors genomics, AI-imaging and software-as-a-service firms that monetize risk models and higher-intensity surveillance; expect genetic-testing and imaging-AI players to gain pricing power while high-volume, low-margin screening centers (outpatient imaging chains) see volume declines. Conservatively model a 5–15% secular decline in routine annual mammography volumes over 2–5 years with a 10–25% increase in targeted advanced imaging/genetic tests for high-risk cohorts, shifting revenue mix from per-scan commodity margins to subscription/licensing and higher ASP devices.

Risk assessment: Tail risks include adverse CMS/USPSTF guidance (policy reversal) or malpractice litigation against risk-based protocols that could stall adoption; these are low probability but high impact over 6–24 months. Hidden dependencies: EMR integration, data-sharing agreements, and payer reimbursement codes; failure here delays revenue capture by 12–36 months. Key catalysts: CMS coverage decisions, large insurer pilots (CVS/UNH/Cigna) and 1–3 courtroom precedents.

Trade implications: Tactical trades should favor diagnostics and software names while underweighting screening-service operators. Use 12–36 month LEAP calls on genetic-testers and imaging-AI (capture adoption lag), and buy 3–12 month put or short exposure to regional imaging center operators if quarterly volumes drop >5% YoY. Rotate sector weight from Healthcare Services -> Diagnostics/HealthTech over next 3–12 months, increasing allocations after explicit payer policy signals.

Contrarian angles: Consensus underestimates device-makers’ ability to upsell high-margin tomosynthesis and integrated LMS software—Hologic/GEHC could be resilient or net beneficiaries, not pure losers. Historical parallel: low-dose CT lung screening took 3–5 years to monetize post-trial; expect similar multi-year revenue ramp rather than immediate disruption. If CMS/USPSTF endorse risk-based screening within 90 days, that would be a convex upside trigger for genetics/AI names and warrants rapid portfolio tilts.

Key Decisions for Investors

• Establish a 2–3% long position in Myriad Genetics (MYGN) via 2027 LEAP calls (near-the-money) to capture multi-year growth in clinical risk/genetic testing; reassess if quarterly genetic test volumes do not grow >10% YoY within 12 months.
• Initiate a 1–2% position in imaging-AI leader ICAD (ICAD) via 12–18 month call options (or 5% cash equity if options illiquid) to play increased demand for AI reads and risk-stratified imaging; add 1% if large payer pilots announced within 90 days.
• Establish a 1–2% short (or buy 3–6 month put spread) on RadNet (RDNT) sized to portfolio volatility—trim or close if monthly screening volumes stabilize or decline <3% YoY; target additional alpha if same-store screening volume falls >5% on a quarterly basis.
• Monitor CMS, USPSTF and major insurer (UNH, CVS, CI) pilot announcements over the next 30–180 days; if CMS issues favorable coverage for risk-based algorithms within 90 days, increase MYGN/ICAD exposure by +1–2% and reduce RDNT short by 50% to lock gains.